Nocdurna (Desmopressin)

Desmopressin, the active ingredient in Nocdurna, is a vasopressin analog presented as a 0.2 mg sublingual tablet for sublingual use. It is indicated for the management of nocturnal enuresis in children and adults, helping to reduce bedwetting episodes.

GNH USA supplies Nocdurna as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled distribution across multiple markets. The company adheres to EU GMP standards and provides regulatory support for importers. Our global logistics network enables timely delivery while maintaining product integrity.

Desmopressin acts on the antidiuretic pathway to reduce urine production during sleep. - Nocturnal enuresis: decreases the number of wet nights by increasing water reabsorption in the kidneys. - Central diabetes insipidus: replaces deficient antidiuretic hormone to reduce excessive urine output. - Primary nocturnal polyuria: limits nighttime urine volume, improving sleep continuity.

Desmopressin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate pain often reported during early treatment. - Nausea: transient stomach upset that usually resolves without intervention. - Nasal congestion: sensation of blocked nasal passages. - Abdominal discomfort: mild cramps or pain. - Flushing: temporary reddening of the skin. - Hyponatremia (mild): low sodium levels without neurological symptoms.

Serious or Rare Side Effects: - Severe hyponatremia: can lead to confusion, seizures, or coma. - Water intoxication: excessive fluid retention causing edema. - Allergic reaction: rash, itching, or swelling of the face and throat. - Thromboembolic events: rare clot formation in veins. - Hypotension: marked drop in blood pressure. - Seizures: neurological events associated with electrolyte imbalance.

Before initiating therapy, clinicians should evaluate patient-specific risk factors. - Fluid restriction: limit excessive fluid intake to reduce hyponatremia risk. - Serum sodium monitoring: check sodium levels regularly, especially in high‑risk patients. - Renal function assessment: adjust use in patients with impaired kidney function. - Elderly caution: older adults may be more susceptible to water retention and electrolyte shifts. - Drug interaction review: avoid concurrent use with other antidiuretic agents. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Desmopressin may interact with several medicines, altering its safety or effectiveness.

Major Interactions (Avoid): - Other antidiuretic agents (e.g., vasopressin analogs): combined use can precipitate severe hyponatremia. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase the risk of water retention and hyponatremia.

Moderate Interactions (Monitor Closely): - Loop diuretics: may reduce desmopressin efficacy by increasing urinary water loss. - Carbamazepine: can enhance desmopressin clearance, lowering its effect. - Alcohol: may potentiate water retention and exacerbate electrolyte disturbances.